Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 plus trastuzumab in previously treated HER2-positive advanced or metastatic breast cancer
NL-OMON36445Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Luminespib and trastuzumab in breast cancer, sponsored by Novartis. Primary endpoints: Incidence rate of dose-limiting toxicities and Overall response rate. Started Feb 2011; status: recruiting.
02
Drugs
Luminespibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON36445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36445.